Literature DB >> 34793866

A new perspective on NAFLD: Focusing on lipid droplets.

Eleonora Scorletti1, Rotonya M Carr2.   

Abstract

Lipid droplets (LDs) are complex and metabolically active organelles. They are composed of a neutral lipid core surrounded by a monolayer of phospholipids and proteins. LD accumulation in hepatocytes is the distinctive characteristic of non-alcoholic fatty liver disease (NAFLD), which is a chronic, heterogeneous liver condition that can progress to liver fibrosis and hepatocellular carcinoma. Though recent research has improved our understanding of the mechanisms linking LD accumulation to NAFLD progression, numerous aspects of LD biology are either poorly understood or unknown. In this review, we provide a description of several key mechanisms that contribute to LD accumulation in hepatocytes, favouring NAFLD progression. First, we highlight the importance of LD architecture and describe how the dysregulation of LD biogenesis leads to endoplasmic reticulum stress and inflammation. This is followed by an analysis of the causal nexus that exists between LD proteome composition and LD degradation. Finally, we describe how the increase in size of LDs causes activation of hepatic stellate cells, leading to liver fibrosis and hepatocellular carcinoma. We conclude that acquiring a more sophisticated understanding of LD biology will provide crucial insights into the heterogeneity of NAFLD and assist in the development of therapeutic approaches for this liver disease.
Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autophagy; Endoplasmic reticulum stress; Hypoxia; Lipid droplets (LDs); Non-alcoholic fatty liver disease (NAFLD); Non-alcoholic steatohepatitis (NASH)

Mesh:

Year:  2021        PMID: 34793866     DOI: 10.1016/j.jhep.2021.11.009

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  15 in total

1.  Magnesium Supplementation Stimulates Autophagy to Reduce Lipid Accumulation in Hepatocytes via the AMPK/mTOR Pathway.

Authors:  Shiyan Chen; Shunkui Luo; Baojia Zou; Jianhui Xie; Jian Li; Yingjuan Zeng
Journal:  Biol Trace Elem Res       Date:  2022-10-13       Impact factor: 4.081

2.  [TSPAN8 is involved in lipid metabolism in non-alcoholic fatty liver disease in mice].

Authors:  J Zhang; W Xue; S Zhang; Y Zhu; C Yang; Y Gao; L Shi; W Huang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-05-20

3.  GOS Ameliorates Nonalcoholic Fatty Liver Disease Induced by High Fat and High Sugar Diet through Lipid Metabolism and Intestinal Microbes.

Authors:  Shuting Qiu; Jiajia Chen; Yan Bai; Jincan He; Hua Cao; Qishi Che; Jiao Guo; Zhengquan Su
Journal:  Nutrients       Date:  2022-07-01       Impact factor: 6.706

4.  Dietary Vitamin E Intake Is Associated With a Reduced Risk of Developing Digestive Diseases and Nonalcoholic Fatty Liver Disease.

Authors:  Eleonora Scorletti; Kate Townsend Creasy; Marijana Vujkovic; Mara Vell; Inuk Zandvakili; Daniel J Rader; Kai Markus Schneider; Carolin V Schneider
Journal:  Am J Gastroenterol       Date:  2022-03-14       Impact factor: 12.045

5.  Acacetin Protects against Non-Alcoholic Fatty Liver Disease by Regulating Lipid Accumulation and Inflammation in Mice.

Authors:  Chian-Jiun Liou; Shu-Ju Wu; Szu-Chuan Shen; Li-Chen Chen; Ya-Ling Chen; Wen-Chung Huang
Journal:  Int J Mol Sci       Date:  2022-04-23       Impact factor: 6.208

Review 6.  HSD17B13: A Potential Therapeutic Target for NAFLD.

Authors:  Hai-Bo Zhang; Wen Su; Hu Xu; Xiao-Yan Zhang; You-Fei Guan
Journal:  Front Mol Biosci       Date:  2022-01-07

7.  MD2 deficiency prevents high-fat diet-induced AMPK suppression and lipid accumulation through regulating TBK1 in non-alcoholic fatty liver disease.

Authors:  Wu Luo; Lin Ye; Xue-Ting Hu; Mei-Hong Wang; Min-Xiu Wang; Lei-Ming Jin; Zhong-Xiang Xiao; Jian-Chang Qian; Yi Wang; Wei Zuo; Li-Jiang Huang; Guang Liang
Journal:  Clin Transl Med       Date:  2022-03

Review 8.  The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment.

Authors:  Lili Yu; Wei Hong; Shen Lu; Yanrong Li; Yaya Guan; Xiaogang Weng; Zhiwei Feng
Journal:  Front Pharmacol       Date:  2022-03-08       Impact factor: 5.810

9.  Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis.

Authors:  Kentaro Murakami; Yusuke Sasaki; Masato Asahiyama; Wataru Yano; Toshiaki Takizawa; Wakana Kamiya; Yoshihiro Matsumura; Motonobu Anai; Tsuyoshi Osawa; Jean-Charles Fruchart; Jamila Fruchart-Najib; Hiroyuki Aburatani; Juro Sakai; Tatsuhiko Kodama; Toshiya Tanaka
Journal:  Cells       Date:  2022-02-18       Impact factor: 6.600

Review 10.  Functions of Stress-Induced Lipid Droplets in the Nervous System.

Authors:  Eva Islimye; Victor Girard; Alex P Gould
Journal:  Front Cell Dev Biol       Date:  2022-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.